Celcuity Inc. (CELC) - 10-Q Summary for Period Ended June 30, 2026
Business Context and Reporting Period
Celcuity Inc. is a biotechnology company developing targeted therapies for solid tumors. The reporting period covers the three and six months ended June 30, 2026. The Company's primary asset is REVTORPYK (gedatolisib), a pan-PI3K and mTORC1/2 inhibitor. While the Company has not yet generated product revenue, it received FDA approval for REVTORPYK on July 14, 2026, a subsequent event to the balance sheet date, triggering a $50.0 million milestone payment to Pfizer.
Key Financial Metrics
| Metric (in thousands) | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(131,705) | $(82,265) |
| Net Loss Per Share (Basic & Diluted) | $(2.41) | $(1.90) |
| Operating Expenses | $116,625 | $80,142 |
| Cash, Cash Equivalents, and Investments | $754,044 | $298,309 |
| Total Debt (Convertible Notes) | $753,235 | $195,324 |
| Accumulated Deficit | $(580,602) | $(354,120) |
Note: The filing does not provide explicit gross margin or operating margin percentages as there is no revenue. The Company is in a pre-revenue commercialization phase.
Material Changes vs. Prior Period
- Debt Restructuring: In June 2026, the Company issued $575.0 million in 0.250% Convertible Senior Notes due 2032. Proceeds were used to fully prepay the Amended A&R Loan Agreement ($137.4 million), resulting in an $11.5 million non-cash loss on debt extinguishment.
- Operating Expenses: Total operating expenses increased 46% year-over-year to $116.6 million. Selling, General, and Administrative (SG&A) expenses surged 276% to $52.5 million, driven by commercial headcount additions and launch preparations for REVTORPYK. Research and Development (R&D) expenses decreased slightly by 3% to $64.1 million due to reduced clinical trial costs for the completed VIKTORIA-1 trial.
- Liquidity: Cash and investments increased significantly from $298.3 million to $754.0 million due to the convertible note issuance and equity offerings, offset by operating cash outflows of $110.5 million.
- Intangible Assets: The Company recognized a $50.0 million intangible asset related to the Pfizer license milestone triggered by the subsequent FDA approval.
Guidance, Outlook, and Risks
- Commercial Launch: Commercial launch activities for REVTORPYK commenced immediately following FDA approval. Shipments are expected to begin in late Q3 2026. The Company estimates a total addressable market of over $6.0 billion annually in the second-line setting.
- Clinical Pipeline: The VIKTORIA-2 Phase 3 trial (first-line setting) is ongoing with topline data expected in 2028 and 2030. The CELC-G-201 Phase 1b/2 trial for metastatic castration-resistant prostate cancer is ongoing.
- Liquidity Outlook: Management believes current cash, cash equivalents, and short-term investments ($754.0 million) are sufficient to fund operations into 2029.
- Risks: Key risks include the ability to achieve commercial success and reimbursement for REVTORPYK, the outcome of ongoing clinical trials, potential need for additional financing, and competition. The Company remains subject to significant operating losses until product sales materialize.
Investor Verification Checklist
- Revenue Recognition Timing: Verify the exact date of first commercial shipment and revenue recognition for REVTORPYK in upcoming filings.
- Debt Conversion Terms: Review the conversion prices for the 2031 Notes ($51.30) and 2032 Notes ($124.53) to assess potential future dilution.
- Commercial Execution: Monitor SG&A expense trends to ensure commercial infrastructure costs align with sales ramp-up expectations.
- Regulatory Milestones: Track the submission and approval status of the supplemental NDA (sNDA) for the PIK3CA mutant cohort, expected in Q3 2026.
- Cash Burn Rate: Assess the sustainability of the current cash position against the projected burn rate as commercialization costs scale.